Literature DB >> 11699414

Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells.

C Pepper1, K Hooper, A Thomas, T Hoy, P Bentley.   

Abstract

We have previously shown that the Bcl-2 antisense oligonucleotide ODN 2009 can induce apoptosis in B-cell chronic lymphocytic leukaemia (B-CLL) cells. In this study we evaluated whether ODN 2009 could increase the sensitivity of B-CLL cells to Chlorambucil-induced cell death in vitro in order to establish whether the notion of antisense-mediated chemosensitisation could be applied to B-CLL. Bcl-2 antisense in combination with Chlorambucil resulted in a more marked reduction in Bcl-2 protein expression (p = 0.003), enhanced Bax expression (p < 0.0001) and increased apoptosis when compared to cells incubated with Chlorambucil alone (p = 0.03). This increased in vitro cytotoxicity demonstrates a proof of the concept that a combination of Bcl-2 antisense oligonucleotides with conventional chemotherapeutic drugs may elicit an enhanced therapeutic effect in B-CLL and should therefore be considered for further investigation in the form of a clinical trial.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11699414     DOI: 10.3109/10428190109064606

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  10 in total

Review 1.  Bcl-2 and apoptosis in chronic lymphocytic leukemia.

Authors:  Aaron D Schimmer; Irene Munk-Pedersen; Mark D Minden; John C Reed
Journal:  Curr Treat Options Oncol       Date:  2003-06

Review 2.  New directions in the diagnosis and treatment of chronic lymphocytic leukaemia.

Authors:  Folke Schriever; Dieter Huhn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

Review 4.  Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.

Authors:  Fevzi F Yalniz; William G Wierda
Journal:  Drugs       Date:  2019-08       Impact factor: 9.546

5.  Sub-millimolar concentration of the novel phenol-based compound, 2-hydroxy benzoate zinc, induces apoptosis in human HT-1080 fibrosarcoma cells.

Authors:  J G Mahdi; C J Pepper; M A Alkarrawi; A J Mahdi; I D Bowen
Journal:  Cell Prolif       Date:  2009-11-17       Impact factor: 6.831

Review 6.  Regulated cell death pathways: new twists in modulation of BCL2 family function.

Authors:  Nidhish Sasi; Misun Hwang; Jerry Jaboin; Ildiko Csiki; Bo Lu
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

7.  Influence of BCL2-938 C>A promoter polymorphism and BCL2 gene expression on the progression of breast cancer.

Authors:  Phanni Bhushann Meka; Sarika Jarjapu; Sandeep Kumar Vishwakarma; Santhoshi Rani Nanchari; Anuradha Cingeetham; Sandhya Annamaneni; Srinivasulu Mukta; B Triveni; Vishnupriya Satti
Journal:  Tumour Biol       Date:  2015-12-11

8.  Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.

Authors:  Fariba Némati; Catherine de Montrion; Guillaume Lang; Laurence Kraus-Berthier; Guillaume Carita; Xavier Sastre-Garau; Aurélie Berniard; David Vallerand; Olivier Geneste; Ludmilla de Plater; Alain Pierré; Brian Lockhart; Laurence Desjardins; Sophie Piperno-Neumann; Stéphane Depil; Didier Decaudin
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

9.  PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.

Authors:  Chao Hu; Mengxia Yu; Yanling Ren; Kongfei Li; Dominic M Maggio; Chen Mei; Li Ye; Juying Wei; Jie Jin; Zhengping Zhuang; Hongyan Tong
Journal:  Sci Rep       Date:  2017-06-06       Impact factor: 4.379

Review 10.  Bcl-2 antisense therapy in B-cell malignant proliferative disorders.

Authors:  Asher Chanan-Khan; Myron S Czuczman
Journal:  Curr Treat Options Oncol       Date:  2004-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.